Sign in Sign up for free

Last updated: 17 August 2022 at 8:19pm EST

Melinda Griffith Net Worth




The estimated Net Worth of Melinda Griffith is at least $183 Thousand dollars as of 15 August 2022. Ms. Griffith owns over 10,000 units of Oncocyte stock worth over $93,000 and over the last 4 years she sold OCX stock worth over $0. In addition, she makes $90,341 as Independent Director at Oncocyte.

Ms. Griffith OCX stock SEC Form 4 insiders trading

Melinda has made over 2 trades of the Oncocyte stock since 2022, according to the Form 4 filled with the SEC. Most recently she bought 10,000 units of OCX stock worth $10,000 on 15 August 2022.

The largest trade she's ever made was buying 10,000 units of Oncocyte stock on 15 August 2022 worth over $10,000. On average, Melinda trades about 5,000 units every 13 days since 2020. As of 15 August 2022 she still owns at least 30,000 units of Oncocyte stock.

You can see the complete history of Ms. Griffith stock trades at the bottom of the page.





Melinda Griffith biography

Melinda Griffith J.D. serves as Independent Director of the Company. Ms. Griffith has been Vice President of Strategic Alliance Management and Chief Legal Counsel at the Parker Institute for Cancer Immunotherapy since 2016. Since 2015, Ms. Griffith has served as the Chair of the Board of Directors of Thrive Networks, a non-profit organization supporting healthcare, water and sanitation, and education projects in Vietnam, Cambodia and Laos. Previously, Ms. Griffith worked at Clarient, Inc., a CLIA-certified cancer testing lab, where she served as Senior Vice President from 2010 through 2013, as General Counsel from 2010 to 2011, and as Chief Compliance Officer and head of Business Development and Product Strategy from 2011 to 2013, where she aided the company through the public tender offer and sale process to GE Healthcare. Ms. Griffith previously served in executive roles at Axys Pharmaceuticals from 1992 to 1995, Genelabs Technologies from 1995 to 1998, Tethys Bioscience from 2008 to 2009, and CardioDx from 2014 to 2015. Additionally, Ms. Griffith served as the global head of licensing and law for Hoffmann La-Roche’s molecular diagnostic business from 1998 to 2007, where she oversaw the worldwide PCR licensing programs and directed its IP strategy and litigation in U.S. and foreign courts and agencies. Ms. Griffith directed GE Healthcare’s Congressional and Medicare lobbying efforts to address CMS coverage and reimbursement determinations for in vitro diagnostic tests from 2011 to 2013, and was on the Board of Directors of the California Clinical Laboratory Association from 2012 to 2013.

What is the salary of Melinda Griffith?

As the Independent Director of Oncocyte, the total compensation of Melinda Griffith at Oncocyte is $90,341. There are 7 executives at Oncocyte getting paid more, with Ronald Andrews having the highest compensation of $2,102,210.



How old is Melinda Griffith?

Melinda Griffith is 65, she's been the Independent Director of Oncocyte since 2019. There are 3 older and 6 younger executives at Oncocyte. The oldest executive at Oncocyte Corporation is Dr. Michael D. West Ph.D., 68, who is the Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc..

What's Melinda Griffith's mailing address?

Melinda's mailing address filed with the SEC is C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE, CA, 92618.

Insiders trading at Oncocyte

Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin..., and Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.



What does Oncocyte do?

oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.



What does Oncocyte's logo look like?

Oncocyte Corporation logo

Complete history of Ms. Griffith stock trades at Oncocyte

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
15 Aug 2022 OCX Oncocyte Corporation Melinda Griffith
Director
 Buy 10,000 $1.00 $10,000
15 Aug 2022
30,000 ↗
24 Jun 2022 OCX Oncocyte Corporation Melinda Griffith
Director
 Option 10,000 $1.02 $10,200
24 Jun 2022
10,000 ↗


Oncocyte executives and stock owners

Oncocyte executives and other stock owners filed with the SEC include: